| Baseline | 3 hours after trial medicine intake | Changes between Baseline and 3 hours after trial medicine intake | ||
| P-AVP (pg/ml) | - tolvaptan | 0.4 ± 0.2 | 1.1 ± 0.5* | −0.7 ± 0.5# |
| - placebo | 0.4 ± 0.2 | 0.3 ± 0.1 | 0.1 ± 0.2 | |
| P-ANGII (pg/ml) | - tolvaptan | 7.8 ± 7.6 | 6.6 ± 3.8 | 1.2 ± 5.3 |
| - placebo | 6.6 ± 4.0 | 5.4 ± 4.1 | 1.2 ± 1.8# | |
| PRC (pg/ml) | - tolvaptan | 7.5 ± 6.1 | 7.6 ± 6.7 | −0.1 ± 1.7 |
| - placebo | 7.5 ± 4.2 | 6.3 ± 3.1 | 1.2 ± 1.5# | |
| P-Aldo (pmol/l) | - tolvaptan | 258.2 ± 171.7 | 248.5 ± 137.1 | 9.7 ± 107.5 |
| - placebo | 253.6 ± 116.1 | 250.6 ± 151.5 | 3.0 ± 107.5 |